Drug firm Suven Life Sciences today announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of major depressive disorder.
In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a "novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing... And the topline results from the study is expected during the quarter Jan-March 2018".
Suven Life CEO Venkat Jasti said: "Progression of SUVN- 911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD)."
Suven Life said the global antidepressant market is valued over USD 20 billion.
Suven Life Sciences shares were trading 1.01 per cent up at Rs 75.80 on BSE in morning trade.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)